Baculovirus-Vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites

Infection and Immunity

Volumn 82, Issue 10, 2014, Pages 4348-4357

  Mizutani, Masanori ^a   Iyori, Mitsuhiro ^a   Blagborough, Andrew M ^b   Fukumoto, Shinya ^c   Funatsu, Tomohiro ^a   Sinden, Robert E ^b   Yoshida, Shigeto ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACULOVIRUS VECTOR; BCG VACCINE; BDES PVCSP G VACCINE; BDES PVS25 GP64 VACCINE; BDES PVS25 PVCSP G VACCINE; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; HYBRID PROTEIN; MALARIA VACCINE; PROTEIN P25; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; DRUG CARRIER; OOKINETE ANTIGEN P25, PLASMODIUM; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE TRANSMISSION; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; GENETIC TRANSDUCTION; HOST PARASITE INTERACTION; IN VITRO STUDY; MALARIA CONTROL; MAMMAL CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE TRANSMISSION; PLASMODIUM VIVAX MALARIA; PROTEIN EXPRESSION; PROTEIN FOLDING; RODENT MALARIA; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE; ANIMAL; BACULOVIRUS; BAGG ALBINO MOUSE; BLOOD; GENE VECTOR; GENETICS; IMMUNOLOGY; MALARIA; PLASMODIUM BERGHEI; PLASMODIUM VIVAX; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BACULOVIRIDAE; DISEASE TRANSMISSION, INFECTIOUS; DRUG CARRIERS; FEMALE; GENETIC VECTORS; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; PLASMODIUM BERGHEI; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84907097045     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02040-14     Document Type: Article

References (43)

1. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI. 2010. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 4:e774. http://dx.doi.org/10.1371/journal.pntd.0000774.
2. Hay SI, Okiro EA, Gething PW, Patil AP, Tatem AJ, Guerra CA, Snow RW. 2010. Estimating the global clinical burden of Plasmodium falciparum malaria in 2007. PLoS Med. 7:e1000290. http://dx.doi.org/10.1371/journal.pmed.1000290.
3. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. 2007. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 77(Suppl):79-87.
4. Kochar DK, Das A, Kochar SK, Saxena V, Sirohi P, Garg S, Kochar A, Khatri MP, Gupta V. 2009. Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern India. Am. J. Trop. Med. Hyg. 80:194-198.
5. Sina B. 2002. Focus on Plasmodium vivax. Trends Parasitol. 18:287-289. http://dx.doi.org/10.1016/S1471-4922(02)02329-2.
6. Picot S. 2006. Is Plasmodium vivax still a paradigm for uncomplicated malaria? Med. Mal. Infect. 36:406-413. (In French.) http://dx.doi.org/10.1016/j.medmal.2006.06.001.
7. Herrera S, Corradin G, Arevalo-Herrera M. 2007. An update on the search for a Plasmodium vivax vaccine. Trends Parasitol. 23:122-128. http://dx.doi.org/10.1016/j.pt.2007.01.008.
8. Carlton JM, Sina BJ, Adams JH. 2011. Why is Plasmodium vivax a neglected tropical disease? PLoS Negl. Trop. Dis. 5:e1160. http://dx.doi.org/10.1371/journal.pntd.0001160.
9. Hoffman SL, Miller LH. 1996. Perspectives on malaria vaccine development, p 1-12. In Hoffman SL (ed), Malaria vaccine development: a multiimmune response approach. American Society for Microbiology, Washington, DC.
10. Shi YP, Das P, Holloway B, Udhayakumar V, Tongren JE, Candal F, Biswas S, Ahmad R, Hasnain SE, Lal AA. 2000. Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate. Vaccine 18:2902-2914. http://dx.doi.org/10.1016/S0264-410X(00)00045-1.
11. Theisen M, Roeffen W, Singh SK, Andersen G, Amoah L, van de Vegte-Bolmer M, Arens T, Tiendrebeogo RW, Jones S, Bousema T, Adu B, Dziegiel MH, Christiansen M, Sauerwein R. 2014. A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages. Vaccine 32:2623-2630. http://dx.doi.org/10.1016/j.vaccine.2014.03.020.
12. Yoshida S, Kawasaki M, Hariguchi N, Hirota K, Matsumoto M. 2009. A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice. Infect. Immun. 77:1782-1789. http://dx.doi.org/10.1128/IAI.01226-08.
13. Iyori M, Nakaya H, Inagaki K, Pichyangkul S, Yamamoto DS, Kawasaki M, Kwak K, Mizukoshi M, Goto Y, Matsuoka H, Matsumoto M, Yoshida S. 2013. Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PLoS One 8:e70819. http://dx.doi.org/10.1371/journal.pone.0070819.
14. Yoshida S, Araki H, Yokomine T. 2010. Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice. Infect. Immun. 78:595-602. http://dx.doi.org/10.1128/IAI.00877-09.
15. Yoshida S, Nagumo H, Yokomine T, Araki H, Suzuki A, Matsuoka H. 2010. Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1-and apical membrane antigen 1-based vaccines. PLoS One 5:e13727. http://dx.doi.org/10.1371/journal.pone.0013727.
16. Mlambo G, Kumar N, Yoshida S. 2010. Functional immunogenicity of baculovirus expressing Pfs25, a human malaria transmission-blocking vaccine candidate antigen. Vaccine 28:7025-7029. http://dx.doi.org/10.1016/j.vaccine.2010.08.022.
17. Blagborough AM, Yoshida S, Sattabongkot J, Tsuboi T, Sinden RE. 2010. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 28:6014-6020. http://dx.doi.org/10.1016/j.vaccine.2010.06.100.
18. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, Kabwende AL, Adegnika AA, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali AM, Mtoro AT, Hamad AS, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kabore B, Sombie O, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson KF, Slutsker L, et al. 2012. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367:2284-2295. http://dx.doi.org/10.1056/NEJMoa1208394.
19. Hisaeda H, Collins WE, Saul A, Stowers AW. 2001. Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism. Vaccine 20:763-770. http://dx.doi.org/10.1016/S0264-410X(01)00402-9.
20. Peiris JS, Premawansa S, Ranawaka MB, Udagama PV, Munasinghe YD, Nanayakkara MV, Gamage CP, Carter R, David PH, Mendis KN. 1988. Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 39:26-32.
21. Carter R. 2001. Transmission blocking malaria vaccines. Vaccine 19: 2309-2314. http://dx.doi.org/10.1016/S0264-410X(00)00521-1.
22. Sumitani M, Kasashima K, Yamamoto DS, Yagi K, Yuda M, Matsuoka H, Yoshida S. 2013. Reduction of malaria transmission by transgenic mosquitoes expressing an antisporozoite antibody in their salivary glands. Insect Mol. Biol. 22:41-51. http://dx.doi.org/10.1111/j.1365-2583.2012.01168.x.
23. Ramjanee S, Robertson JS, Franke-Fayard B, Sinha R, Waters AP, Janse CJ, Wu Y, Blagborough AM, Saul A, Sinden RE. 2007. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine 25:886-894. http://dx.doi.org/10.1016/j.vaccine.2006.09.035.
24. Lim CS, Tazi L, Ayala FJ. 2005. Plasmodium vivax: recent world expansion and genetic identity to Plasmodium simium. Proc. Natl. Acad. Sci. U. S. A. 102:15523-15528. http://dx.doi.org/10.1073/pnas.0507413102.
25. Zhou J, Blissard GW. 2008. Display of heterologous proteins on gp64null baculovirus virions and enhanced budding mediated by a vesicular stomatitis virus G-stem construct. J. Virol. 82:1368-1377. http://dx.doi.org/10.1128/JVI.02007-07.
26. malERA Consultative Group on Vaccines. 2011. A research agenda for malaria eradication: vaccines. PLoS Med. 8:e1000398. http://dx.doi.org/10.1371/journal.pmed.1000398.
27. Goodman AL, Blagborough AM, Biswas S, Wu Y, Hill AV, Sinden RE, Draper SJ. 2011. A viral vectored prime-boost immunization regime targeting the malaria pfs25 antigen induces transmission-blocking activity. PLoS One 6:e29428. http://dx.doi.org/10.1371/journal.pone.0029428.
28. Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A. 2014. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infect. Immun. 82:1277-1286. http://dx.doi.org/10.1128/IAI.01187-13.
29. Persson C, Oliveira GA, Sultan AA, Bhanot P, Nussenzweig V, Nardin E. 2002. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. J. Immunol. 169:6681-6685. http://dx.doi.org/10.4049/jimmunol.169.12.6681.
30. Espinosa DA, Yadava A, Angov E, Maurizio PL, Ockenhouse CF, Zavala F. 2013. Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy. Infect. Immun. 81:2882-2887. http://dx.doi.org/10.1128/IAI.00461-13.
31. Sack BK, Miller JL, Vaughan AM, Douglass A, Kaushansky A, Mikolajczak S, Coppi A, Gonzalez-Aseguinolaza G, Tsuji M, Zavala F, Sinnis P, Kappe SH. 2014. Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect. Immun. 82:808-817. http://dx.doi.org/10.1128/IAI.01249-13.
32. Medica DL, Sinnis P. 2005. Quantitative dynamics of Plasmodium yoelii sporozoite transmission by infected anopheline mosquitoes. Infect. Immun. 73:4363-4369. http://dx.doi.org/10.1128/IAI.73.7.4363-4369.2005.
33. Vaughan AM, Kappe SH. 2012. Malaria vaccine development: persistent challenges. Curr. Opin. Immunol. 24:324-331. http://dx.doi.org/10.1016/j.coi.2012.03.009.
34. Teixeira LH, Tararam CA, Lasaro MO, Camacho AG, Ersching J, Leal MT, Herrera S, Bruna-Romero O, Soares IS, Nussenzweig RS, Ertl HC, Nussenzweig V, Rodrigues MM. 2014. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents. Infect. Immun. 82:793-807. http://dx.doi.org/10.1128/IAI.01410-13.
35. Vidor E. 2007. The nature and consequences of intra-and inter-vaccine interference. J. Comp. Pathol. 137(Suppl 1):S62-S66. http://dx.doi.org/10.1016/j.jcpa.2007.04.014.
36. Rogers WO, Weiss WR, Kumar A, Aguiar JC, Tine JA, Gwadz R, Harre JG, Gowda K, Rathore D, Kumar S, Hoffman SL. 2002. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect. Immun. 70:4329-4335. http://dx.doi.org/10.1128/IAI.70.8.4329-4335.2002.
37. Zhou Z, Todd CW, Wohlhueter RM, Price A, Xiao L, Schnake P, Bonner PC, Martin AM, Goldman IF, De La Vega P, Udhayakumar V, Lal AA. 2006. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli. Hum. Vaccin. 2:14-23. http://dx.doi.org/10.4161/hv.2.1.2437.
38. Sedegah M, Charoenvit Y, Minh L, Belmonte M, Majam VF, Abot S, Ganeshan H, Kumar S, Bacon DJ, Stowers A, Narum DL, Carucci DJ, Rogers WO. 2004. Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther. 11:448-456. http://dx.doi.org/10.1038/sj.gt.3302139.
39. Jiang G, Charoenvit Y, Moreno A, Baraceros MF, Banania G, Richie N, Abot S, Ganeshan H, Fallarme V, Patterson NB, Geall A, Weiss WR, Strobert E, Caro-Aquilar I, Lanar DE, Saul A, Martin LB, Gowda K, Morrissette CR, Kaslow DC, Carucci DJ, Galinski MR, Doolan DL. 2007. Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization. Malar. J. 6:135. http://dx.doi.org/10.1186/1475-2875-6-135.
40. Jiang G, Shi M, Conteh S, Richie N, Banania G, Geneshan H, Valencia A, Singh P, Aguiar J, Limbach K, Kamrud KI, Rayner J, Smith J, Bruder JT, King CR, Tsuboi T, Takeo S, Endo Y, Doolan DL, Richie TL, Weiss WR. 2009. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS One 4:e6559. http://dx.doi.org/10.1371/journal.pone.0006559.
41. Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, Charoenvit Y, Epstein JE, Luke T, Freilich DA, Norman J, Hoffman SL. 2005. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect. Immun. 73:2863-2872. http://dx.doi.org/10.1128/IAI.73.5.2863-2872.2005.
42. Sedegah M, Charoenvit Y, Aguiar J, Sacci J, Hedstrom R, Kumar S, Belmonte A, Lanar DE, Jones TR, Abot E, Druilhe P, Corradin G, Epstein JE, Richie TL, Carucci DJ, Hoffman SL. 2004. Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF. Genes Immun. 5:553-561. http://dx.doi.org/10.1038/sj.gene.6364125.
43. Forbes EK, Biswas S, Collins KA, Gilbert SC, Hill AV, Draper SJ. 2011. Combining liver-and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference. J. Immunol. 187:3738-3750. http://dx.doi.org/10.4049/jimmunol.1003783.